- Over 75% of the GNM value stems from North America and Europe. If patients in low-to-middle-income regions, particularly in emerging markets such as Africa, begin accessing therapy in increasing numbers, the market has much potential to grow.
- The neuroscience diagnostic market is primarily driven by medical imaging and next-generation sequencing technologies. Effective implementation of early diagnosis is paramount for the optimal intervention and management of brain disorders. Physicians increasingly demand hybrid technologies combining various imaging techniques to improve diagnostic accuracy. Together with rising investments in AI-based imaging by health care companies and high-tech players, these trends support the growth projection.
- Pharmacological interventions dominate the neuroscience drug market against multiple sclerosis, anxiety, mood disorders and substance abuse disorders. The current allocation of drug innovation does not represent patient needs, leading to an underserved CNS drug market.
- The neuroscience non-drug market is dominated by the low-growth segment of behavioural therapy services. Digital health interventions accounted for only 0.8% of non-drug therapies revenue in 2022, but the low-value segment of digital health is expected to experience sizable growth over the coming years. Digital health companies are developing non-pharmacological approaches by combining diverse technological components, including software, hardware or artificial intelligence.
- Current revenue levels and future growth rates negatively correlate across GNM segments, which indicates high-value segments display low CAGR forecasts, while low-value segments have significant growth potential.
The analysis reflects Deloitte’s current view on potential investment opportunities in neuroscience by presenting a selection of segments, their forecasted returns, and estimated growth rates, based also on regional differentiators and local developments. The global neuroscience market offers attractive return potential. Investment bodies may infer future growth, and therefore projected return on investment based on current revenue levels across segments of the global neuroscience market. Moreover, private equity, venture capital and corporate M&A organisations may adjust their investment strategy according to the target region.
link